Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 2137087
PUBLISHER: GlobalData | PRODUCT CODE: 2137087
Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2026
PUBLISHED:
PAGES: 321 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
GlobalData's clinical trial report, "Duchenne Muscular Dystrophy - Global Clinical Trials Review, 2026" provides an overview of Duchenne Muscular Dystrophy Clinical trials scenario. This report provides top line data relating to the clinical trials on Duchenne Muscular Dystrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Product Code: GDHC7369CTIDB
Table of Contents
Table of Contents
List of Tables
List of Figures
- Report Guidance
- GlobalData Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Duchenne Muscular Dystrophy Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Duchenne Muscular Dystrophy
- Jul 30, 2026: Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
- Jul 29, 2026: The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy
- Jul 09, 2026: Satellos' oral DMD drug improves arm movement after six months in Phase II
- Jul 07, 2026: Presentation of New Clinical Data on Givinostat in Duchenne Muscular Dystrophy at ICNMD 2026
- Jul 01, 2026: Santhera Announces Topline Results From Catalyst Pharmaceuticals' Phase 1 Clinical Trial of AGAMREE
- Jun 26, 2026: Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026
- Jun 26, 2026: Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
- Jun 26, 2026: Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
- Jun 25, 2026: Satellos to Present Clinical Program Updates at ICNMD 2026
- Clinical Trial Profile Snapshots
Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About GlobalData
- Contact Us
- Source
Product Code: GDHC7369CTIDB
List of Table
List of Tables
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region, 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase, 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
List of Figure
List of Figures
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, G7 Countries (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Duchenne Muscular Dystrophy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Duchenne Muscular Dystrophy to Genetic Disorders Clinical Trials, E7 Countries (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Duchenne Muscular Dystrophy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Duchenne Muscular Dystrophy Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Duchenne Muscular Dystrophy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Duchenne Muscular Dystrophy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- GlobalData Methodology
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.